Introduction and Objective: Although certain glucagon-like peptide-1 receptor agonists (GLP1RA) are approved for the treatment of youth with Type 2 Diabetes Mellitus or obesity in the United States, they are increasingly used in youth with Type 1 Diabetes Mellitus (T1D) with obesity or insulin resistance at our center. We sought to understand the effects of GLP1RA use in these youth. Methods: This retrospective observational cohort study identified youth with T1D who were prescribed GLP1RA between January 1, 2019 and December 31, 2025 with at least one follow up visit. Clinical outcomes between baseline to the last visit on treatment were compared for a maximum of 4 follow up visits. Medians and interquartile ranges (IQR) were reported. Results: Eighteen patients were identified. GLP1RAs prescribed were semaglutide and liraglutide, median age at baseline was 16.65 years (IQR 15.66, 18.22), and 78% had private insurance. The median time for follow up was 283.5 days (IQR 168, 378). The median change in hemoglobin A1c (A1c) was -0.60% (-1.00, -0.20), basal insulin dose was -10.10 units (-14.50, -0.90), and body mass index (BMI) was -2.00 (-3.16, -1.05). More outcomes are included in Table 1. Conclusion: GLP1RA use in youth with T1D resulted in clinically meaningful decreases in A1c, basal insulin dose, and BMI. Prospective data in larger cohorts are needed to better understand the effectiveness of GLP1RA use in this population and risk for hypoglycemia. Disclosure E. Choi: None. A. Jergel: None. K. Cossen: None. D.S. Hsia: Advisory Panel; Current; Eli Lilly and Company. Other - I conduct clinical trials under agreements between this company and my institution.; Current; Eli Lilly and Company, Novo Nordisk.
Choi et al. (Fri,) studied this question.